YOLFTbeta
30

Wuhan Hvsen Biotechnology Co Ltd

300871 · SHE · Healthcare / Biotechnology

17.61CNY+0.17 (+0.97%)

Price History

Full chart

Market Stats

Previous Close17.44
Open17.80
Day Range17.28 – 18.10
52-Week Range18.67 – 31.92
Volume5.51M
Market Cap4.26B
P/E (TTM)12.79
Forward P/E0.00
EPS1.65
Dividend Yield2.37%
Beta0.59
50-Day Avg22.14
200-Day Avg24.02

About

Wuhan Hvsen Biotechnology Co.,Ltd. is involved in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company provides tylvalosin tartrate powders, and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products, as well as Tildipirosin. It produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. was founded in 2002 and is based in Wuhan, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jie Han
  • Employees1.13K
  • HeadquartersNo.208 Zhangbai Road, Wuhan, China, 430042, China
  • Websitehttps://www.whhsyy.com

Leadership

  • Mr. Jie HanGeneral Manager · b. 1985
  • Mr. Kaijie YangDeputy GM & CFO · b. 1970
  • Mr. Zexiang LiuDirector & Assistant to the GM · b. 1976
  • Mr. Qingfeng WangBoard Secretary · b. 1989
  • Mr. Jinbin HuangDeputy General Manager · b. 1982
  • Mr. Shuo LiDeputy General Manager · b. 1980
  • Mr. Hujie YuDeputy General Manager · b. 1985
  • Qiongbi LuoAccounting Supervisor
  • Ms. Hongxia LiDirector of Warehousing & Logistics Data and Supervisor · b. 1976
  • Mr. Wenge DingProduct & Technical Service Director and Supervisor · b. 1969

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue257.78M399.72M421.87M427.22M777.46M996.22M1.02B1.02B1.20B1.68B
Growth (%)-+55.06%+5.54%+1.27%+81.98%+28.14%+2.68%-0.31%+17.71%+40.07%
Cost of Revenue123.64M197.54M239.36M265.05M491.59M727.71M800.16M809.11M1.01B1.16B
Gross Profit134.15M202.18M182.51M162.17M285.87M268.51M222.75M210.65M194.72M520.99M
Gross Margin52.04%50.58%43.26%37.96%36.77%26.95%21.78%20.66%16.22%30.99%
Operating Expense79.60M98.80M101.02M83.61M109.35M117.48M163.59M195.57M223.80M218.73M
Operating Income54.54M103.38M81.49M78.56M176.52M151.03M59.16M15.08M-29.09M302.25M
Operating Margin21.16%25.86%19.32%18.39%22.70%15.16%5.78%1.48%-2.42%17.98%
EBITDA65.49M113.63M94.84M92.88M197.74M182.25M138.10M161.05M127.18M422.63M
EBITDA Margin25.40%28.43%22.48%21.74%25.43%18.29%13.50%15.79%10.60%25.14%
Net Income49.44M88.42M71.40M68.77M150.16M132.87M52.71M16.78M-20.16M253.16M
Net Income Margin19.18%22.12%16.92%16.10%19.31%13.34%5.15%1.65%-1.68%15.06%
R&D12.77M17.95M20.36M21.11M28.38M46.89M28.24M44.60M55.80M79.82M
R&D as % of Total Revenue4.95%4.49%4.83%4.94%3.65%4.71%2.76%4.37%4.65%4.75%
Interest Expense155.30K417.90K1.55M2.19M2.62M3.27M18.82M28.22M43.02M13.62M
Interest Expense % of Total Revenue0.06%0.10%0.37%0.51%0.34%0.33%1.84%2.77%3.58%0.81%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets255.86M344.18M466.60M650.08M1.75B2.74B2.99B2.98B3.01B3.01B
Total Liabilities101.16M121.06M142.08M271.80M373.08M1.12B1.45B1.47B1.55B822.17M
Total Equity154.69M223.11M324.52M378.28M1.38B1.62B1.54B1.51B1.46B2.17B
Cash52.28M53.44M99.45M104.46M345.34M1.07B424.04M293.61M326.14M310.20M
Total Debt1.00M1.00M25.00M75.58M72.70M680.98M790.45M842.24M872.24M-
Net Debt-51.28M-52.44M-74.45M-28.88M-272.64M-387.25M366.40M548.63M546.09M-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow60.00M80.56M21.10M105.24M48.35M155.72M96.68M92.92M43.53M238.45M
Investing Cash Flow-27.92M-56.16M-34.02M-122.95M-670.44M-185.15M-749.54M-100.30M-101.81M-
Financing Cash Flow-13.18M-24.42M53.37M21.88M825.72M710.09M-34.60M-41.48M13.98M-
Capital Expenditure27.97M56.40M34.05M123.06M230.84M600.12M428.87M184.31M194.43M96.92M
Free Cash Flow32.03M24.16M-12.96M-17.82M-182.49M-444.40M-332.18M-91.39M-150.89M141.53M
Dividends Paid19.77M24.38M21.63M15.00M5.99M45.31M54.91M48.97M59.16M49.92M
FCF to OCF53.39%29.99%-61.43%-16.93%-377.45%-285.39%-343.59%-98.36%-346.63%59.35%
Dividend Paid to FCF61.72%100.91%-166.92%-84.19%-3.28%-10.20%-16.53%-53.58%-39.20%35.27%

Earnings

Report DateSep 30, 2020Mar 29, 2021Apr 27, 2021Jul 30, 2021Oct 28, 2021Mar 10, 2022Apr 22, 2022Aug 29, 2022Oct 25, 2022Dec 31, 2022Apr 26, 2023Aug 28, 2023Oct 29, 2023Jan 12, 2024Apr 24, 2024Aug 27, 2024Sep 30, 2024Dec 31, 2024Apr 28, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------
EPS Actual0.270.320.570.230.110.080.010.030.120.160.160.01-0.010.01-0.10-0.220.030.170.250.390.350.280.380.64
Surprise------------------------
Timing-After-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hours-Pre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-market--Pre-market-----

Key Statistics & Ratios

Market Cap4.26B
Enterprise Value4.24B
Trailing P/E12.79
Forward P/E0.00
Price / Sales2.47
Price / Book1.88
EPS1.65
Book Value11.54
Revenue (TTM)1.72B
Gross Profit (TTM)600.06M
EBITDA433.04M
Profit Margin19.82%
Operating Margin16.89%
Return on Equity15.59%
Return on Assets6.06%
Shares Outstanding201.78M
Shares Float104.38M
Beta0.59
Dividend Yield2.37%
Dividend Rate0.50
Payout Ratio30.31%

Dividends

20262×
0.30Sep 8, 20260.20Jul 6, 2026
20252×
0.10Aug 26, 20250.11Jun 4, 2025
20241×
0.27May 29, 2024
20231×
0.30Jun 21, 2023
20221×
0.33Apr 13, 2022
20211×
0.27May 10, 2021

Stock Splits

  • May 10, 20211.5:1